Results for Solid Tumors

Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.

Dr. Surrey participates in collaborative research within the fields of pediatric pathology and molecular oncology. She has an interest in pediatric solid tumors, particularly sarcomas.

Dr. Richman's research focuses on chimeric antigen receptor (CAR) T cells targeting solid tumors with the goal of translating these findings to this unmet clinical need.

Dr. Chorny's research program focuses on nanomedicines as well as drug, cell, and gene delivery systems for treating proliferative disease. His current research specifically focuses on the use of nanoparticle-mediated delivery to solid tumors and site-specific delivery for cardiovascular disease.

Dr. Bassiri studies the ways in which the immunometabolic features of lymphocytes are altered within solid tumor environments, and how modulating these features may enhance anti-tumor immunity.

Dr. Wolpaw works on inflammatory signaling in childhood solid tumors, particularly neuroblastoma. The hope is that understanding these pathways and how to modify them will allow us to rationally design approaches to enhance the efficacy of immunotherapies.

Dr. Ma focuses on immune engineering. He leverages genetic, chemistry, and engineering tools to dissect immune cell-cell and cell-tissue crosstalk and harness these crosstalk mechanisms to develop biomaterials, protein, and cell-based precision immunotherapies for cancer and autoimmune diseases.

Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.

Dr. Hocking’s research aims to better understand the neurodevelopmental consequences of having survived childhood cancer or having neurofibromatosis type 1, to identify those who are most at risk for poor outcomes, and to intervene in some way in order to improve quality of life.

Dr. Cole is a pediatric neuro-oncologist who has dedicated her career to translational and clinical research, combining her expertise in molecular pathology, cancer genomics, and developmental therapeutics to identify novel treatments for children with cancer.